Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in hepatitis c virus/hiv-coinfected persons: The aids clinical trials group a5178 study

Clinical Infectious Diseases

Volumn 55, Issue 5, 2012, Pages 631-638

  Butt, Adeel A ^a,b   Umbleja, Triin ^c   Andersen, Janet W ^c   Sherman, Kenneth E ^d   Chung, Raymond T ^e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; LIPID METABOLISM; LIPOPROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84864924223     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis463     Document Type: Article

References (31)

1. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C infection. Host, viral and environmental factors. JAMA 2000; 284:450-6.
2. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005; 3:241-9.
3. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31:1090-101.
4. Butt AA, Wang X, Budoff M, Leaf DA, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49:225-32.
5. Kuo YH, Chuang TW, Hung CH, et al. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. J Formos Med Assoc 2011; 110:363-71.
6. Lange CM, von WM, Bojunga J, et al. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and ribavirin. Eur J Gastroenterol Hepatol 2010; 22:1303-7.
7. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009; 50:1030-7.
8. Tada S, Saito H, Ebinuma H, et al. Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. Hepatol Res 2009; 39:195-9.
9. Mehta SH, Brancati FL, Sulkowski MS, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2001; 133:592-9.
10. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38:50-6.
11. Deltenre P, Louvet A, Lemoine M, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55:1187-94.
12. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34:297-305.
13. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50:712-8.
14. Hung CH, Wang JH, Hu TH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16:2265-71.
15. Vachon ML, Factor SH, Branch AD, et al. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol 2011; 54:41-7.
16. Cacoub P, Carrat F, Bedossa P, et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 study. Antivir Ther 2009; 14:839-45.
17. Merchante N, de lS-G I, Merino D, et al. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol 2009; 50:684-92.
18. Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011; 140:469-77.
19. Kim HJ, Park JH, Park DI, et al. Clearance of HCV by combination therapy of pegylated interferon alpha-2a and ribavirin improves insulin resistance. Gut Liver 2009; 3:108-15.
20. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102:570-6.
21. Giordanino C, Bugianesi E, Smedile A, et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008; 103:2481-7.
22. Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. Incidence, predictors and management of anemia and its association with virologic response in HCV/HIV coinfected persons treated with long term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther 2011; 33:1234-44.
23. Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAMC). J Acquir Immune Defic Syndr 2010; 55:597-605.
24. Evans SR, Fichtenbaum CJ, Aberg JA. Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals. ACTG 5087. HIV Clin Trials 2007; 8:45-52.
25. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52:854-63.
26. Fujino T, Nakamuta M, Yada R, et al. Expression profile of lipid metabolism- associated genes in hepatitis C virus-infected human liver. Hepatol Res 2010; 40:923-9.
27. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52:864-74.
28. Delgado-Borrego A, Jordan SH, Negre B, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8:458-62.
29. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48:721-7.
30. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52:1799-805.
31. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53:693-700.